Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Nicole M. Daniel"'
Autor:
Gargi Patel, Nicole M. Daniel, Vishal Patel, Nicole Leonida, Steven Smoke, Jessica Gerges, Akshar Patel, Henry Leach, Karan Raja, Monica Shah
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics
What is known and Objective A pandemic can strain all aspects of the healthcare system, including the ability to monitor the safety of medication use. Reviewing the adequacy of medication safety practices during the COVID‐19 pandemic is critical to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b60c3f3f8edd43bb015d6c6f3fe45d0d
https://doi.org/10.1111/jcpt.13429
https://doi.org/10.1111/jcpt.13429
Autor:
Karan Raja, Mitesh Patel, Nicole M. Daniel, Mona Philips, Jessica Gerges, Mark Attalla, Soo Kang, Donald Beggs, Susan Morrison, Naveen Ballem, Brandon Chen, Komal Nadeem, Ruben Patel
Publikováno v:
Journal of pharmacy practice.
Background: Tocilizumab is an interleukin-6 receptor antagonist hypothesized to blunt the uncontrolled immune response, cytokine release syndrome, in severe COVID-19 and prevent attributable morbidity and mortality. Objective: The objective of this s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b794be08a0227d0699835ae34eaed6a
https://pubmed.ncbi.nlm.nih.gov/34231415
https://pubmed.ncbi.nlm.nih.gov/34231415
Publikováno v:
International Journal of Antimicrobial Agents
Severe COVID-19 (coronavirus disease 2019) is associated with elevated inflammatory markers, consistent with cytokine release syndrome (CRS). Tocilizumab is an interleukin-6 (IL-6) inhibitor effective in treating CRS secondary to chimeric antigen rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0a157bc5685442b78009590607e73c3
https://pubmed.ncbi.nlm.nih.gov/33338559
https://pubmed.ncbi.nlm.nih.gov/33338559
Publikováno v:
Open Forum Infectious Diseases
Background Severe Covid-19 is associated with elevated inflammatory markers, consistent with cytokine release syndrome (CRS). Tocilizumab is an IL-6 inhibitor, effective in treating CRS secondary to CAR-T cell therapy. The efficacy of tocilizumab in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cad961b9869c95c3af0cbbc85d02948a
http://europepmc.org/articles/PMC7776342
http://europepmc.org/articles/PMC7776342
Autor:
Nicole M. Daniel, Megan Maroney
Publikováno v:
Journal of Clinical Psychopharmacology. 40:212-213
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f0b15739303d98d960f5e88bee2df22
https://doi.org/10.1097/jcp.0000000000001190
https://doi.org/10.1097/jcp.0000000000001190